文献速递哮喘

美泊利单抗治疗严重嗜酸性哮喘伴激素依赖患者的法国早期准入项目结果

Mepolizumab in a population with severe eosinophilic asthma and corticosteroid dependence: results from a French early access programme.
PubMed 文献 · Eur Respir J · 2020-06-25

本研究为法国早期准入项目(nATU)的回顾性观察研究,纳入146例接受至少一剂美泊利单抗的严重嗜酸性哮喘患者,随访至24个月。结果显示年急性发作次数从基线5.8次降至0.6次,口服激素使用比例从92.8%降至34.7%,血嗜酸性粒细胞计数从722 cells·µL-1降至92 cells·µL-1,安全性和临床结局均改善。

要点

  • 美泊利单抗可显著减少严重嗜酸性哮喘患者的年急性发作次数。
  • 治疗24个月后口服激素依赖比例从92.8%降至34.7%。
  • 血嗜酸性粒细胞计数从722降至92 cells·µL-1,肺功能与哮喘控制同步改善。

核心结论

  • 在真实世界严重嗜酸性哮喘伴激素依赖人群中,美泊利单抗与多项临床结局的显著改善相关,且安全性良好。

研究设计与样本

  • 法国早期准入项目(nATU)的回顾性观察研究,分析医院病历资料至治疗开始后24个月。
  • 共纳入146例接受至少一剂美泊利单抗的严重嗜酸性哮喘患者。

主要发现

  • 基线时患者平均年龄58.2岁,严重哮喘平均病程13.4年,37.0%有呼吸道过敏。
  • 年急性发作次数从基线5.8次降至24个月时的0.6次,需住院和急诊就诊的发作分别从0.6和0.5次降至0.1和0.1次。
  • 口服激素使用比例从基线92.8%降至24个月时的34.7%。
  • 平均血嗜酸性粒细胞计数从基线722 cells·µL-1降至24个月时的92 cells·µL-1,肺功能和哮喘控制呈相似趋势。

临床怎么用

  • 对于严重嗜酸性哮喘且依赖口服激素的患者,美泊利单抗可作为减少急性发作和激素用量的治疗选择。

局限性

  • 本研究为回顾性观察性研究,非随机对照试验,可能存在混杂偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Mepolizumab was available in France as part of an early access programme for patients with severe eosinophilic asthma (nominative autorisation temporaire d'utilisation [temporary use authorisation] (nATU)) before its commercialisation. This study aimed to characterise patients who received mepolizumab in the nATU. METHODS: This retrospective, observational study analysed data from the hospital medical records of patients up to 24 months after treatment initiation. Study objectives were to describe patient baseline characteristics, the evolution of disease severity and treatment modifications during follow-up; safety was also investigated. FINDINGS: Overall, 146 patients who received ≥1 dose of mepolizumab were included. At inclusion, patients had a mean age of 58.2 years with a mean severe asthma duration of 13.4 years, and 37.0% had respiratory allergies. Patients experienced, on average, 5.8 exacerbations per patient per year at baseline, 0.6 and 0.5 of which required hospitalisation and emergency department visits, respectively. These values improved to 0.6, 0.1 and 0.1 exacerbations per patient per year, respectively, at 24 months of follow-up. Most patients (92.8%) were using oral corticosteroids at baseline, compared with 34.7% by 24 months of follow-up. Moreover, mean blood eosinophil counts improved from 722 cells·µL-1 at baseline to 92 cells·µL-1 at 24 months of follow-up; lung function and asthma control followed a similar trend. INTERPRETATION: Results confirm findings from clinical trials, demonstrating that mepolizumab is associated with important improvements in several clinically meaningful outcomes and has a favourable safety profile in a population with severe eosinophilic asthma, outside of the controlled environment of a clinical trial.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Taillé C, Chanez P, Devouassoux G, et al. Mepolizumab in a population with severe eosinophilic asthma and corticosteroid dependence: results from a French early access programme. Eur Respir J. 2020. PMID: 32241829. doi:10.1183/13993003.02345-2019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。